Ampio: Early Positive Data in Phase 1 Ampion in COVID-19 Respiratory Distress

 - Subjects who received Ampion treatment required less oxygen than standard of care alone.

- Subjects who received Ampion treatment were stable or had improvement on the Ordinal Scale for Clinical Improvement (Ordinal Scale) compared to the standard of care patients.

- Subjects who received Ampion treatment were stable or had improvement on the National Early Warning Score 2 scoring system (NEWS2) compared to the of standard of care patients.

- Ampion improved all-cause mortality in COVID-19 patients with respiratory distress compared to standard of care.

- There have been no drug-related serious adverse events.

- Ampio has inventory on hand. In event the safety and efficacy study is successful, and the product receives regulatory approval, Ampio is in a position to begin immediate manufacturing.

https://www.prnewswire.com/news-releases/ampio-announces-early-positive-data-in-phase-1-trial-of-inhaled-ampion-in-covid-19-respiratory-distress-301219046.html